CYTHRO – 500

CYTHRO 500

AZITHROMYCIN 500 MG

Mechanism of Action:
Macrolides inhibit protein synthesis. They impair the elongation cycle of the peptidyl chain by specifically binding to the 50 S subunit of the ribosome.

Pharmacodynamics:
Macrolides produce time-dependent killing.

Pharmacokinetics:
Azithromycin is acid-stable antibiotic, so it can be taken orally with no need of protection from gastric acids. It is readily absorbed, but absorption is greater on an empty stomach. Time to peak concentration (Tmax) in adults is 2.1 to 3.2 hours for oral dosage forms. Due to its high concentration in phagocytes, azithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations are released. The concentration of azithromycin in the tissues can be over 50 times higher than in plasma, due to ion trapping and its high lipid solubility (volume of distribution is too high).

Azithromycin’s half-life allows a large single dose to be administered and yet maintain bacteriostatic levels in the infected tissue for several days.

Shelf life:

3 years

Half-life:
 35-40 hours

Adverse Effects:

Gastrointestinal: abdominal cramps, nausea, diarrhea, anorexia, pancreatitis
Genitourinary: vulvovaginal candidiasis, renal failure
Cardiovascular System: prolongation of QT interval
Hepatic: hepatotoxicity, jaundice
Hematologic: eosinophilia, thrombocytosis, lymphopenia
Central Nervous System: headache, fatigue
Endocrine/Metabolic: hyperglycemia
Dermatologic: itching, nail discoloration

Pregnancy:

Category B: No evidence of risk in humans but studies inadequate.

Monitoring Requirements:


Therapeutic: 
Periodic WBC, chest X-ray if pneumonia, cultures, temperature

Drug Interactions:

Due to its hepatic metabolism, caution should be exercised when administering this agent with other drugs metabolized in the liver. The following drug interactions are clinically relevant but do not represent the comprehensive list of documented or potential drug-drug interactions.

Contraindications/Warnings/Precautions:

Contraindicated: Coadministration with astemizole, cisapride, ergotamine, terfenadine
Precautions: May prolong the QTc interval.
Special precautions for storage
Do not store above 25°C.

Overdose

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required